Charcot-Marie-Tooth Disease clinical trials at University of California Health
1 research study open to eligible people
“The PREMIER study is now enrolling subjects to test a new investigational treatment for CMT1A!”
open to eligible people ages 16-65
The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1A. This double-blind study will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.
at UC Davis UCLA